Treatment of Diabetes After Gastric Bypass With Sitagliptin (LAF33)
|ClinicalTrials.gov Identifier: NCT01512797|
Recruitment Status : Completed
First Posted : January 19, 2012
Results First Posted : February 23, 2018
Last Update Posted : February 23, 2018
|Condition or disease||Intervention/treatment|
|Type 2 Diabetes Mellitus||Drug: Sitagliptin phosphate Other: Placebo|
Januvia (sitagliptin phosphate 100mg) is an FDA approved medication for the treatment of Type 2 Diabetes. Sitagliptin works by inhibiting the Dipeptidyl peptidase-4 enzyme, resulting in increased active glucagon-like peptide-1 (GLP-1) levels. GLP-1 is an incretin which increases post-prandial insulin secretion. Because Gastric Bypass has also been shown to increase GLP-1 levels, this study seeks to determine the additional effect of DDP-4 inhibition on glucose control in patients who have elevated incretin levels post Gastric Bypass. The study will also assess if Januvia (Sitagliptin phosphate) is safe and well tolerated in patients after Gastric Bypass.
Recruitment and data collection for this study was started at St. Luke's Hospital in New York, NY and later moved to Columbia University Medical Center in New York, NY.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||37 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Assess Efficacy, Safety and Tolerability of Sitagliptin Phosphate 100 mg as Treatment for Recurrent, Persistent or Newly Diagnosed Type 2 Diabetes After Gastric Bypass|
|Study Start Date :||July 2012|
|Primary Completion Date :||August 2016|
|Study Completion Date :||August 2016|
Active Comparator: Sitagliptin phosphate
100 mg/day sitagliptin phosphate (Januvia) PO once a day for 4-5 weeks
Drug: Sitagliptin phosphate
100 mg/day orally
Other Name: Januvia
Placebo Comparator: Placebo
1 Placebo pill / day PO once a day for 4-5 weeks
1 Placebo Pill per day
- Change in Postprandial Glucose Levels After Mixed Meal Test [ Time Frame: Baseline and ~4 weeks ]Glucose levels were measured in study participants while fasting and periodically over 3 hours after drinking a 200 kcal mixed meal test, before and after intervention (Sitagliptin or Placebo).
- Change in Area Under the Curve (AUC) Glucose Levels After Mixed Meal Test [ Time Frame: Baseline and ~4 weeks ]Glucose levels were measured in study participants while fasting and periodically over 3 hours after drinking a 200 kcal mixed meal test, before and after intervention (Sitagliptin or Placebo). AUC was measured by trapezoidal method.
- Effect of Sitagliptin vs Placebo on Satiety in Patients With Type 2 Diabetes After Gastric Bypass Surgery [ Time Frame: Baseline and ~4 weeks ]Satiety levels were measured in study participants while they were fasting and periodically over a three hour period after drinking a 200 kcal meal drink, before and after intervention via a Visual Analog Scale. Participants were asked to mark on a 0 to 150 millimeter scale their response to the following question: "How full do you feel right now?" with lower scores indicating "not full at all" and higher scores indicating "extremely full."
- Occurrence of Side Effects In Relation to Sitagliptin [ Time Frame: 6 weeks ]Side effects to Sitagliptin or Placebo were measured in study participants via Sigstad score questionnaire, while fasting and periodically during a 3 hour period after drinking a 200 kcal meal drink, before and after intervention. The Sigstad scoring system is based on the participants report of the occurrence of 16 symptoms suggestive of the dumping syndrome. Each symptom is given a different score. For example, desire to sit down (+4), breathlessness (+3), dizziness (+2), nausea (+1), vomiting (-4) etc.The scale can range from -5 to 34. Scores greater than or equal to 7, after glucose intake, are considered diagnostic of dumping syndrome.
- Active GLP-1 [ Time Frame: Pre-Intervention and Post-Intervention ]Active GLP-1 (Fasting and during a Mixed Meal Test). The Change in Fasting Active GLP-1 refers to the change in fasting active GLP-1 from pre-intervention time point to post-intervention time point. The Change in Peak Active GLP-1 refers to the change in the peak active GLP-1 level from the pre-intervention time point to post-intervention time point.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01512797
|United States, New York|
|New York Obesity Nutrition Research Center, Columbia University|
|New York, New York, United States, 10032|
|Principal Investigator:||Blandine Laferrere, MD||New York Obesity Nutrition Research Center|